Home › trial
 

Keywords :   


Tag: trial

Ariad Pharma Discontinues Phase III Trial of Ponatinib (Iclusig) in Leukemia Patients

2013-10-20 13:07:47| Biotech - Topix.net

Ariad Pharmaceuticals, Inc. has announced that it is discontinuing the phase III EPIC trial of ponatinib in patients with newly diagnosed chronic myeloid leukemia .

Tags: iii trial phase patients

 

Free broadband via gaps in spectrum gets biggest trial

2013-10-17 10:28:32| Wireless - Topix.net

The first mass trials of white-space wireless technology in Europe are giving the much-hyped idea a chance of breaking out into the real world WHITE space radio is not exactly in the last chance saloon, but it is close.

Tags: free trial biggest spectrum

 
 

UPDATE 1-Regeneron, Sanofi drug slashes cholesterol in late-stage trial

2013-10-16 10:56:26| Biotech - Topix.net

A new type of cholesterol drug being developed by Regeneron Pharmaceuticals Inc and Sanofi SA, when used by itself, cut levels of "bad" LDL cholesterol almost in half in the first of a dozen late-stage trials of the injectable medicine.

Tags: update trial drug cholesterol

 

Results of Phase II PRECEDENT Trial for Investigational Folate Receptor Therapy Vintafolide in Patients with Platinum-Resistant Ovarian Cancer Published in Journal of Clinical Oncology

2013-10-14 23:02:00| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION N.J., & WEST LAFAYETTE, Ind. Merck and Endocytes Phase III PROCEED pivotal trial of vintafolide in ovarian cancer ongoing WHITEHOUSE STATION N.J., & WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, (NYSE: MRK) and Endocyte, Inc. (NASDAQ: ECYT) today announced the online publication of results from the randomized Phase II PRECEDENT trial for vintafolide (MK-8109/EC145), an investigational folate small molecule drug conjugate (SMDC), in the Journal of Clinical Oncology (JCO), the official journal of the American Society of Clinical Oncology. Language: English Contact: MerckMedia:Caroline Lappetito,267-305-7639Caroline.Lappetito@Merck.comorClaire Mulhearn, 908-423-7425Claire.Mulhearn@Merck.comorInvestors:Carol Ferguson, 908-423-4465Carol.Ferguson@Merck.comorJustin Holko, 908-423-5088Justin_Holko@Merck.comorEndocyteMedia:Tony Russo, 212-845-4251Tony.Russo@Russopartnersllc.comorMartina Schwarzkopf, 212-845-4292Martina.Schwarzkopf@Russopartnersllc.comorInvestors:Stephanie Ascher, 212-362-1200Stephanie@sternir.com Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: ECYT Exchange: NASDAQ read more

Tags: of results journal published

 

Toyota wins unintended acceleration bellwether trial

2013-10-11 04:30:19| Green Car Congress

Tags: trial toyota wins acceleration

 

Sites : [172] [173] [174] [175] [176] [177] [178] [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] next »